Waters (WAT) Valuation Check After Conference Updates And Renewed Goldman Sachs Support
Conference messages and analyst attention put Waters back in focus
Waters (WAT) has moved back onto investors' radar after its recent health care conference comments on growth priorities and BD Diagnostic Solutions integration, alongside a renewed supportive view from a major Wall Street bank.
See our latest analysis for Waters.
After a weak patch that left the 90 day share price return at a 20.35% decline and the 1 year total shareholder return at an 11.85% loss, recent gains around the TD Cowen health care conference and renewed Wall Street attention suggest that negative momentum may be easing.
If Waters has you reconsidering your watchlist, this could be a good moment to widen the search and review 37 healthcare AI stocks
With shares still down double digits over 1 year but trading at roughly a 30% discount to both analyst targets and intrinsic estimates, is Waters quietly offering value, or is the market already accounting for its next phase of growth?
Most Popular Narrative: 22.6% Undervalued
With Waters last closing at $304.24 against a narrative fair value of $393.14, the gap between market price and modeled worth is hard to ignore.
The planned combination with BD's Biosciences and Diagnostic Solutions business is expected to accelerate entry into biologics, precision medicine, and cell/gene therapy markets, segments with expanding analytical needs, unlocking new addressable markets and providing a multi-year revenue synergy opportunity, directly impacting future revenues and EPS growth.
Want to see what is powering that valuation gap? The narrative leans heavily on faster top line expansion, firmer margins, and a rich future earnings multiple. Curious how those pieces add up to that fair value.
Result: Fair Value of $393.14 (UNDERVALUED)
Have a read of the narrative in full and understand what's behind the forecasts.
However, this depends on Waters executing the BD deal cleanly and avoiding prolonged weakness in academic and government demand, which could challenge those upbeat analyst assumptions.
Find out about the key risks to this Waters narrative.
Another way to look at Waters' valuation
The analyst narrative and fair value model lean toward upside, but the current P/E of 46.4x tells a different story, especially against the Life Sciences industry at 33.8x, peers at 28.3x, and a fair ratio of 24.7x that the market could eventually lean towards. Is the optimism already in the price, or do you think the market is misreading the story?
For a closer look at what these gaps might mean for valuation risk or opportunity, including how earnings growth expectations interact with that higher P/E, See what the numbers say about this price — find out in our valuation breakdown.
Next Steps
Mixed signals or a fresh setup for Waters? If you want to move quickly and build your own view using the full picture, weigh up the 4 key rewards and 1 important warning sign
Looking for more investment ideas?
If Waters has sharpened your thinking, do not stop there. Widen your opportunity set now so you are not looking back wishing you had acted sooner.
- Target income potential with steady cash returns by scanning companies in the 12 dividend fortresses.
- Hunt for quality at a discount by reviewing the 62 high quality undervalued stocks before prices move away from you.
- Prioritize capital protection by focusing on companies in the 67 resilient stocks with low risk scores that aim to keep volatility in check.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com